Literature DB >> 21617582

Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment.

Hiromichi Ito1, Kaori Ito, Michael D'Angelica, Mithat Gonen, David Klimstra, Peter Allen, Ronald P DeMatteo, Yuman Fong, Leslie H Blumgart, William R Jarnagin.   

Abstract

BACKGROUND: This study evaluates the significance of tumor involvement of the liver in early T-stage tumors and lymph node (LN) metastases on outcome after R0 resection of gallbladder cancer (GBCA).
METHODS: A prospectively maintained database, supplemented with review of the medical record, was used to identify patients who underwent a complete (R0) resection for GBCA. All patients underwent definitive surgical treatment at the initial operation (1 stage) or after initial noncurative cholecystectomy (incidental tumors, 2 stage), including partial hepatectomy and portal LN dissection, with or without bile duct and/or adjacent organ resection. Clinicopathological variables, including TNM stage, histologic tumor involvement of liver (residual or direct extension in the GB fossa or discontiguous disease), and the total number of regional LNs assessed were analyzed for their association with outcome.
RESULTS: One hundred twenty-two patients were identified and analyzed. The median follow up period was 23 months. Liver and nodal involvement by GBCA were observed in 61 (50%) and 41(34%) patients, respectively. Among patients with T2 tumors (n = 53), 48 (91%) were incidental. Liver involvement was present in 26%, and this factor was associated with decreased recurrence-free (RFS) and disease-specific survival (DSS) compared with patients with T2 tumors without liver involvement (median RFS, 12 months vs. not reached, P = 0.004, median DSS 25 months versus not reached, P = 0.003); T1b tumors (n = 10) were not associated with liver involvement. The median total lymph node count (TLNC) was 3 (range 0-20). For the entire cohort, survival of patients classified as N0 based on TLNC < 6 was significantly worse than that of N0 patients based on TLNC ≥ 6 (median RFS, 22 months versus not reached, P < 0.001, median DSS 41 months versus not reached, P < 0.001). Liver involvement and TLNC remained significant prognostic factors in a multivariate model that included TNM stage.
CONCLUSION: Resection and histologic evaluation of at least 6 lymph nodes improves risk-stratification after resection of GBCA. Incidental T2 tumors are often associated with residual liver disease and should be reclassified to reflect the adverse outcome. The data suggests a need for standardized minimum requirements for adequate surgical treatment and pathological examination.

Entities:  

Mesh:

Year:  2011        PMID: 21617582     DOI: 10.1097/SLA.0b013e31822238d8

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  70 in total

1.  Relevance of residual disease after liver resection for incidental gallbladder cancer.

Authors:  Javier C Lendoire; Luis Gil; Fernando Duek; Carlos Quarin; Verónica Garay; Gabriel Raffin; Marcelo Rivaldi; Oks Alejandra; Oscar Imventarza
Journal:  HPB (Oxford)       Date:  2012-06-08       Impact factor: 3.647

2.  Radical resection of gallbladder cancer: could it be robotic?

Authors:  Bai-Yong Shen; Qian Zhan; Xia-Xing Deng; Han Bo; Qin Liu; Cheng-Hong Peng; Hong-Wei Li
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

3.  Minimally invasive versus the conventional open surgical approach of a radical cholecystectomy for gallbladder cancer: a retrospective comparative study.

Authors:  Anil K Agarwal; Amit Javed; Raja Kalayarasan; Puja Sakhuja
Journal:  HPB (Oxford)       Date:  2015-02-28       Impact factor: 3.647

4.  Long-term outcomes of incidental gallbladder carcinoma without additional resection: A single institution experiment.

Authors:  Tomohiro Sugiyama; Kenta Makino; Yukiko Fukui; Hiromitsu Kinoshita; Akira Miki; Shigeki Uchida; Michihiko Tsubono; Yasushi Adachi
Journal:  Mol Clin Oncol       Date:  2020-06-02

Review 5.  Key factors influencing prognosis in relation to gallbladder cancer.

Authors:  Charles Henry Caldow Pilgrim; Ryan T Groeschl; Kiran K Turaga; T Clark Gamblin
Journal:  Dig Dis Sci       Date:  2013-05-22       Impact factor: 3.199

Review 6.  The Landmark Series: Gallbladder Cancer.

Authors:  Adriana C Gamboa; Shishir K Maithel
Journal:  Ann Surg Oncol       Date:  2020-05-30       Impact factor: 5.344

7.  Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes.

Authors:  John M Creasy; Debra A Goldman; Vikas Dudeja; Maeve A Lowery; Andrea Cercek; Vinod P Balachandran; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Michael I D'Angelica; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2017-02-13       Impact factor: 6.113

8.  Gallbladder cancer: expert consensus statement.

Authors:  Thomas A Aloia; Nicolas Járufe; Milind Javle; Shishir K Maithel; Juan C Roa; Volkan Adsay; Felipe J F Coimbra; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

9.  Benefit of extended radical surgery for incidental gallbladder carcinoma.

Authors:  Junpei Yamaguchi; Yuji Kaneoka; Atsuyuki Maeda; Yuichi Takayama; Shunsuke Onoe; Masatoshi Isogai
Journal:  Surg Today       Date:  2015-06-17       Impact factor: 2.549

10.  Incidental Gallbladder Cancer on Cholecystectomy: Strategy for Re-resection of Presumed Benign Diseases from a Retrospective Multicenter Study by the Yokohama Clinical Oncology Group.

Authors:  Ryusei Matsuyama; Kenichi Matsuo; Ryutaro Mori; Mitsutaka Sugita; Naotaka Yamaguchi; Toru Kubota; Kunio Kameda; Yasuhisa Mochizuki; Ryo Takagawa; Toshiaki Kadokura; Goro Matsuda; Noriyuki Kamiya; Itaru Endo
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.